We discuss early results from an ongoing study of a triple combination therapy with a PD-L1 checkpoint inhibitor for treating Richter’s transformation.
and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.
Dr. Mato and Dr. Woyach discusses the results of a study looking at which features might predict the future development of Richter’s syndrome in patients treated with ibrutinib.
Richter’s Transformation Richter’s Transformation First described in 1928, Richter’s Transformation (RT), also called Richter’s Syndrome (RS), occurs when CLL / SLL changes into a related but much more aggressive large cell
This research was presented by Dr. Romain Guieze and colleagues at the American Society for Hematology annual meeting which was held December 2021 (ASH 2021).
Ask the Doctor Question: What prognostic value is exon 15 braf mutation discovery with no tp53, no 17p, no trisonomy 12, no del 11q, but Unmutated status? Am I in line
CLL Society On Demand Ed Forum: ASH 2020 Comes to You – Session 3: New Combinations, New Sequences, New Ways to Measure Disease + CAR-T for Richters Recorded Thursday, February 4,
June 2026 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL. Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.
In an early-stage clinical trial, half of patients with relapsed / refractory Richter transformation responded to treatment with BTK degrader BGB-16673.
